For patients who are very elderly, my approach depends on the patient's performance status, other comorbidities, disease features/disease behavior, and indications for treatment. There are patients with MCL who can be observed at diagnosis (those with leukemic non-nodal disease but also those with l...

Broad question. Briefly, if fit for therapy, I think there are chemotherapeutic options, inclusive of cytarabine and autoSCT consolidation, that can provide durable disease benefit. But, important to consider disease burden and proliferative status, as well as TP53 mutation status, before embarking ...